Concepedia

Maxim Soloviev

MS

Statistics

Publications

13

Citations

666

H-Index

13

Active since

1995

Affiliations

Incyte (United States)(Current)

Cleveland Clinic

Case Western Reserve University

Cleveland Foundation

Ashland (United States)

Maxim Soloviev is an author at Incyte (United States) specializing in medicine, pharmacology, and cancer pharmacology.

Publications per year

1995–2021

13

Publications

13

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models

Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu et al. · PLoS ONE · 2020 · 161 citations · Full text

Medicine, Oncology, Pharmacology +14

Limitations of the Mass Isotopomer Distribution Analysis of Glucose to Study Gluconeogenesis

Stephen F. Previs, Charles A. Fernandez, Dawei Yang et al. · Journal of Biological Chemistry · 1995 · 84 citations · Full text

Life Sciences, Biochemistry, Cellular Biochemistry +13

Discovery of Pemigatinib: A Potent and Selective Fibroblast Growth Factor Receptor (FGFR) Inhibitor

Liangxing Wu, Colin Zhang, Chunhong He et al. · Journal of Medicinal Chemistry · 2021 · 74 citations · Full text

Medicine, Oncology, Pharmacology +16

Whole Blood Platelet Aggregation in Humans and Animals: A Comparative Study

Maxim Soloviev, Yukio Okazaki, Hiroaki Harasaki · Journal of Surgical Research · 1999 · 66 citations

Medicine, Hematology, Hematology Physiology +13

Parsaclisib Is a Next-Generation Phosphoinositide 3-Kinase δ Inhibitor with Reduced Hepatotoxicity and Potent Antitumor and Immunomodulatory Activities in Models of B-Cell Malignancy

Niu Shin, Matthew C. Stubbs, Holly K. Koblish et al. · Journal of Pharmacology and Experimental Therapeutics · 2020 · 51 citations · Full text

Medicine, Oncology, Pharmacology +13

1–5 of 13